Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are an established treatment in estrogen receptor-positive breast cancer and are currently in clinical development in melanoma, a tumor that exhibits high rates of CDK4 activation. We analyzed melanoma cells with acquired resistance to the CDK4/6 inhib...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Proc Natl Acad Sci U S A
Prif Awduron: AbuHammad, Shatha, Cullinane, Carleen, Martin, Claire, Bacolas, Zoe, Ward, Teresa, Chen, Huiqin, Slater, Alison, Ardley, Kerry, Kirby, Laura, Chan, Keefe T., Brajanovski, Natalie, Smith, Lorey K., Rao, Aparna D., Lelliott, Emily J., Kleinschmidt, Margarete, Vergara, Ismael A., Papenfuss, Anthony T., Lau, Peter, Ghosh, Prerana, Haupt, Sue, Haupt, Ygal, Sanij, Elaine, Poortinga, Gretchen, Pearson, Richard B., Falk, Hendrik, Curtis, David J., Stupple, Paul, Devlin, Mark, Street, Ian, Davies, Michael A., McArthur, Grant A., Sheppard, Karen E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: National Academy of Sciences 2019
Pynciau:
PNAS Plus
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6731642/
https://ncbi.nlm.nih.gov/pubmed/31439820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1901323116
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg